甘李药业GLR1044注射液临床试验获批

Core Viewpoint - Ganli Pharmaceutical (603087) announced the approval of clinical trials for its investigational drug GLR1044 injection by the National Medical Products Administration, marking a significant step in its development pipeline [1] Group 1: Company Developments - Ganli Pharmaceutical's wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., received the clinical trial approval notice for GLR1044 injection [1] - GLR1044 injection is a biosimilar to Dupixent (dupilumab), aimed at treating moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription therapies [1]